Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Texas Liver Institute
Homepage:
txliver.com
ROR:
03yk6x532
OpenAlex ID:
I4210138836
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
2013
·
Eric Lawitz
, Alessandra Mangia
, et al.
·
New England Journal of Medicine
·
1,788
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
2014
·
Nezam Afdhal
, K. Rajender Reddy
, et al.
·
New England Journal of Medicine
·
1,307
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
2019
·
Zobair M Younossi
, Vlad Ratziu
, et al.
·
The Lancet
·
1,260
PDF
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
2014
·
Kris V. Kowdley
, Stuart C. Gordon
, et al.
·
New England Journal of Medicine
·
1,130
PDF
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
2013
·
Ira M. Jacobson
, Stuart C. Gordon
, et al.
·
New England Journal of Medicine
·
1,090
PDF
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
2014
·
Fred Poordad
, Christophe Hezode
, et al.
·
New England Journal of Medicine
·
874
PDF
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
2015
·
Graham R. Foster
, Nezam Afdhal
, et al.
·
New England Journal of Medicine
·
846
PDF
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
2014
·
Eric Lawitz
, Mark S Sulkowski
, et al.
·
The Lancet
·
818
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
2015
·
Michael P. Curry
, Jacqueline G. O’Leary
, et al.
·
New England Journal of Medicine
·
804
PDF
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
2015
·
David R. Nelson
, James N. Cooper
, et al.
·
Hepatology
·
689
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
2018
·
Mazen Noureddin
, Aarshi Vipani
, et al.
·
The American Journal of Gastroenterology
·
578
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
2017
·
Rohit Loomba
, Eric Lawitz
, et al.
·
Hepatology
·
549
PDF
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
2018
·
Arun Sanyal
, Edgar D Charles
, et al.
·
The Lancet
·
547
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
2013
·
Eric Lawitz
, Fred F Poordad
, et al.
·
The Lancet
·
547
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
2023
·
Rohit Loomba
, Manal F Abdelmalek
, et al.
·
The Lancet. Gastroenterology & hepatology
·
525
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
·
Stefan Zeuzem
, Ira M. Jacobson
, et al.
·
New England Journal of Medicine
·
517
PDF
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
2020
·
Stephen A. Harrison
, Vincent Wai-Sun Wong
, et al.
·
Journal of Hepatology
·
493
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
2016
·
Fred Poordad
, Eugene R. Schiff
, et al.
·
Hepatology
·
460
PDF
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
2020
·
Beth A. Davison
, Stephen A. Harrison
, et al.
·
Journal of Hepatology
·
443
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
2018
·
Stefan Zeuzem
, Graham R. Foster
, et al.
·
New England Journal of Medicine
·
439
PDF
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
2017
·
Edward Gane
, Eric Lawitz
, et al.
·
New England Journal of Medicine
·
400
PDF
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
2018
·
Stephen A. Harrison
, Manal F. Abdelmalek
, et al.
·
Gastroenterology
·
382
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
2014
·
Michael Manns
, Patrick Marcellin
, et al.
·
The Lancet
·
376
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
2021
·
Samer Gawrieh
, Mazen Noureddin
, et al.
·
Hepatology
·
374
PDF
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
2019
·
Naga Chalasani
, Manal F. Abdelmalek
, et al.
·
Gastroenterology
·
357
PDF
Show more works
View as search
Works count:
487
Citation count:
72,030
Year
Topic
Type
